Table 1.
Baseline characteristics of 355 PLWH enrolled in the SCOLTA cohorts, according to the treatment group.
| FTC/TAF/BIC N = 147 |
3TC/TDF/DOR N = 147 |
DTG/DOR N = 61 |
||||||
|---|---|---|---|---|---|---|---|---|
| N or mean or median | % or ±SD or IQR | N or mean or median | % or ±SD or IQR | p ∗ | N or mean or median | % or ±SD or IQR | p ∗∗ | |
| Age, years, median (IQR) | 52 | 44–58 | 52 | 43–57 | 0.92 | 58 | 54–62 | < 0.0001 |
| Male sex, n (%) | 111 | 75.5% | 111 | 75.5% | 1.00 | 44 | 72.1% | 0.75 |
| Caucasian, n (%) | 131 | 89.1% | 130 | 88.4% | 0.85 | 56 | 91.8% | 0.40 |
| BMI (kg/m2), mean ± SD | 25.6 | ±4.1 | 26.1 | ±5.1 | 0.46 | 25.5 | ±4.4 | 0.46 |
| Risk factors for HIV acquisition, n (%) | 0.0002 | 0.93 | ||||||
| Sexual | 72 | 49.0% | 107 | 72.8% | 43 | 70.5% | ||
| IVDU | 32 | 21.8% | 18 | 12.2% | 8 | 13.1% | ||
| Others or unknown | 43 | 29.2% | 22 | 15.0% | 10 | 16.4% | ||
| HBsAg positive, n (%) missing | 12 30 |
8.2% 18.6% |
13 16 |
8.8% 9.9% |
0.93 | 1 6 |
1.6% 9.0% |
0.044 |
| HCV-Ab positive§, n (%) missing | 38 27 |
25.8% 19.7% |
21 14 |
14.3% 10.2% |
0.003 | 13 4 |
21.3% 8.2% |
0.087 |
| CD4 (cells/mm3), median (IQR) | 602 | 457–890 | 758 | 527–941 | 0.004 | 656 | 514–871 | 0.12 |
| CD4/CD8 ratio, median (IQR) | 0.83 | 0.52–1.24 | 0.96 | 0.70–1.29 | 0.036 | 0.86 | 0.64–1.28 | 0.24 |
| Previous treatment duration, years, median (IQR) | 9.5 | 3.1–20.1 | 10.0 | 4.8–17.2 | 0.32 | 21.3 | 11.5–25.4 | < 0.0001 |
| Previous regimen included, n (%) | ||||||||
| TDF | 7 | 4.8% | 36 | 24.5% | < 0.0001 | 1 | 1.6% | < 0.0001 |
| TAF | 93 | 63.3% | 63 | 42.9% | 0.0005 | 18 | 29.5% | 0.037 |
| PI | 14 | 9.5% | 17 | 11.6% | 0.57 | 33 | 54.1% | < 0.0001 |
| INSTI | 94 | 64.0% | 61 | 41.5% | 0.0001 | 47 | 77.0% | < 0.0001 |
| NNRTI | 12 | 8.2% | 70 | 47.6% | < 0.0001 | 13 | 21.3% | < 0.0001 |
| Dual regimen | 6 | 4.1% | 13 | 8.8% | 0.10 | 31 | 50.8% | < 0.0001 |
| Hypertension, n (%) | 32 | 21.8% | 33 | 22.4% | 0.89 | 31 | 50.8% | 0.0003 |
| Diabetes, n (%) | 14 | 9.5% | 2 | 1.4% | 0.002 | 8 | 13.1% | 0.001 |
| Dyslipidemia, n (%) | 35 | 23.8% | 35 | 23.8% | 1.00 | 29 | 47.5% | 0.001 |
| On statin treatment, n (%) | 18 | 12.2% | 18 | 12.2% | 1.00 | 17 | 27.8% | 0.006 |
| On any lipid-lowering treatments, n (%) | 22 | 15.0% | 24 | 16.3% | 0.75 | 22 | 30.1% | 0.026 |
| Polypharmacy, n (%) | 0.88 | 0.003 | ||||||
| 0 | 71 | 48.3% | 60 | 40.8% | 13 | 21.3% | ||
| 1-2 | 43 | 29.2% | 58 | 39.5% | 24 | 39.3% | ||
| ≥ 3 | 33 | 22.4% | 29 | 19.7% | 24 | 39.3% | ||
| Total cholesterol (mg/dL), mean ± SD | 192 | ±39 | 203 | ±43 | 0.016 | 197 | ±51 | 0.35 |
| LDL-c (mg/dL), mean ± SD | 107 | ±36 | 126 | ±37 | < 0.0001 | 114 | ±42 | 0.042 |
| HDL-c (mg/dL), mean ± SD | 56 | ±20 | 50 | ±15 | 0.0007 | 50 | ±17 | 0.90 |
| Triglycerides (mg/dL), median (IQR) | 114 | 85–159 | 120 | 84–173 | 0.57 | 130 | 97–196 | 0.20 |
| Total cholesterol/HDL-c, mean ± SD | 3.73 | ±1.32 | 4.36 | ±1.27 | < 0.0001 | 4.27 | ±1.61 | 0.67 |
| eGFR (mL/min), mean ± SD | 88.5 | ±21.8 | 91.8 | ±21.6 | 0.18 | 75.8 | ±28.2 | < 0.0001 |
Note: HBsAG: hepatitis B surface antigen; HDL-c: high-density cholesterol; INSTI: integrase strand transfer inhibitors; LDL-c: low-density cholesterol; TAF: tenofovir alafenamide.
Abbreviations: BMI, body mass index; eGFR; estimated glomerular filtration rate; HCV, hepatitis C virus; IVDU, intravenous drug use; NNRTI, non-nucleoside reverse-transcriptase inhibitors; PI, protease inhibitors; PLWH, people living with HIV; TDF, tenofovir disoproxil fumarate.
§4 people with detectable HCVRNA.
∗Comparison between 3-drug regimens.
∗∗Comparison between doravirine-including regimens.